This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Kirby, M. G Search for Related Content Social Bookmarking                         What's this?

NICE and hypertension — the judge's decision is final!

The Surgery, Nevells Road, Letchworth, Herts, SG6 4TS, UK, kirbym{at}globalnet.co.uk

On 28th June 2006 the National Institute for health and Clinical Excellence (NICE) announced their revised guidelines on the treatment of hypertension, which will have a major impact on prescribing practice.¹ With the media excitement surrounding these new guidelines, there is also likely to be an influx of patients concerned about their current medication. This article explains the changes to the guidelines, the evidence behind them and discusses the implications for clinicians.

Key Words: hypertension • NICE • beta blockers • ACE inhibitors • ASCOT.

References

• Hypertension: management of hypertension in adults in primary care. NICE clinical guidelines 34 (Partial update of NICE clinical guideline 18). June 2006.
• Williams B., Poulter NR, Brown MJ et al. Guidelines for management of hypertension report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 2004;18:139-85.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Turnbull F. Blood pressure lowering treatment trialists' collaboration. Effects of different BP lowering regimens on major cardiovascular events: results of prospectively designed overviews of randomised trials. Lancet 2003;362:1527-35.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Carlberg B., Samuelsson O., Lindholm LH Atenolol in hypertension: is it a wise choice? Lancet 2004;364:1684-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Dahlof B., Sever PS, Poulter NR et al. for the ASCOT investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial - Blood Pressure Lowering Arm (ASCOT-BPLA): a multi-centre randomised controlled trial. Lancet 2005;366:895-906.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

The British Journal of Diabetes & Vascular Disease, Vol. 6, No. 4, 177-179 (2006)
DOI: 10.1177/14746514060060040601


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Kirby, M. G Search for Related Content Social Bookmarking                         What's this?